News

Pfizer announced that it has entered into a definitive agreement to acquire all the shares of Therachon Holding AG, a privately-held clinical-stage biotechnology company focused on rare…
Read More...

Akcea Therapeutics and Ionis Pharmaceuticals announced that WAYLIVRA has received conditional marketing authorization from the European Commission (EC) as an adjunct to diet in adult…
Read More...

Novartis announced results from a validation study of the innovative, algorithm-based digital solution MS Progression Discussion Tool, or MSProDiscuss. The tool aims to support and…
Read More...

Merck, known as MSD outside the United States and Canada, announced the presentation of results of a Phase 3 trial evaluating the efficacy and safety of BELSOMRA (suvorexant) C-IV for…
Read More...

Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle) product platform, announced a collaboration with…
Read More...

Verve Therapeutics announced its launch to discover and develop therapies that safely edit the adult human genome to permanently reduce a person’s risk of coronary artery disease, the…
Read More...

The European Commission has approved Dupixent (dupilumab) for use in adults and adolescents 12 years and older as an add-on maintenance treatment for severe asthma with type 2…
Read More...

Pfizer Inc. announced that the European Commission (EC) granted conditional marketing authorization for LORVIQUA (lorlatinib, available in the U.S., Canada and Japan under the brand…
Read More...

Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, announced a clinical trial collaboration with AstraZeneca to…
Read More...

Ligand Pharmaceuticals Incorporated announces the acquisition of economic rights to SB206 from Novan, Inc. SB206 is a Phase 3 topical antiviral gel for the treatment of skin infections,…
Read More...

Xencor announced that the first patient has been dosed in XmAb23104-01 (DUET-3), a Phase 1 clinical study to evaluate the safety and tolerability of XmAb23104, a bispecific antibody…
Read More...

On May 3, the U.S. Food and Drug Administration approved Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) capsules for the treatment of the heart disease (cardiomyopathy) caused…
Read More...

Skyhawk Therapeutics announced a strategic collaboration with Takeda Pharmaceutical Company Limited (Takeda) in which Skyhawk will use its SkySTAR technology platform to discover and…
Read More...

The U.S. Food and Drug Administration approved Ruzurgi (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in patients 6 to less than 17 years of age.…
Read More...

Samsung BioLogics and GI Innovation signed a Contract Development Organization (CDO) contract for immunochemotherapy at Samsung BioLogics headquarters on Thursday. GI Innovation…
Read More...

Sartorius Stedim Biotech (SSB) is introducing its new generation of ambr 15 cell culture automated microbioreactor system. The Generation 2 is the successor to the well-established ambr…
Read More...

AMAL Therapeutics (AMAL), a Swiss biotech developing novel, peptide-based therapeutic cancer vaccines, announces that it has entered into a collaborative agreement with Boehringer…
Read More...

Amgen and Syapse announced a precision medicine collaboration in oncology. Under the terms of the agreement, Amgen and Syapse will develop observational research analytics to assess…
Read More...

Takeda Pharmaceutical Company Limited announced the opening of a new research facility in San Diego, California. Extending Takeda’s 14-year presence in San Diego, the…
Read More...

Abbott announced that m-PIMA HIV-1/2 VL, the world's first point-of-care viral load diagnostic test, has received the World Health Organization's Prequalification approval (WHO PQ). The…
Read More...